| Filed On | Filing |
|---|---|
| 13 Nov 2026 |
Form 4: Farrell Michael J., Director
Gave up 8,111.385 shares to cover exercise price or tax ($1.9M) |
| 13 Nov 2026 |
Form 4: Bloomer Aaron, Chief Financial Officer
Gave up 1,095.137 shares to cover exercise price or tax ($256K) |
| 13 Nov 2026 |
Form 4: Farrell Peter C, Director
Gave up 169.142 shares to cover exercise price or tax ($39.6K) |
| 13 Nov 2026 |
Form 4: De Witte Jan, Director
Gave up 59.981 shares to cover exercise price or tax ($14K) |
| 13 Nov 2026 |
Form 4: Gill Harjit, Director
Gave up 35.731 shares to cover exercise price or tax ($8.36K) |
| 13 Nov 2026 |
Form 4: Rider Michael J, Global General Counsel
Gave up 1,943.5 shares to cover exercise price or tax ($455K) |
| 12 Nov 2026 |
Form 4: Farrell Michael J., Director
Received 4,993 shares by exercise or conversion ($731K) · Sold 4,993 shares ($1.18M) |
| 09 Nov 2026 | 144 |
| 30 Oct 2026 | 10-Q |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition; Other Events
Q1 revenue increased by 6% to $1.4 billion; up 7% on a core constant currency basis |
| 26 Oct 2026 |
Form 4: Rider Michael J, Global General Counsel
Sold 400 shares ($102K) |
| 23 Oct 2026 | 144 |
| 08 Oct 2026 |
Form 4: Farrell Michael J., Director
Received 4,991 shares by exercise or conversion ($730K) · Sold 4,991 shares ($1.13M) |
| 07 Oct 2026 | 144 |
| 01 Oct 2026 | ARS |
| 01 Oct 2026 | DEFA14A |
| 01 Oct 2026 |
Proxy statement: annual meeting on November 18, 2026
CEO pay $16.2M, up 10% · say-on-pay vote |
| 01 Oct 2026 |
Form 4/A: Farrell Michael J., Director
Holds 479,803 shares of ResMed Common Stock |
| 01 Oct 2026 |
Form 4: Leong Justin, Chief Product Officer
Received 6,461 shares as a grant or award |
| 01 Oct 2026 |
Form 4: Rider Michael J, Global General Counsel
Received 3,230 shares as a grant or award |
Loading...